Review of the application of RNA interference technology in the pharmaceutical industry.
Ribonucleic acid (RNA) interference (RNAi) is a recently discovered phenomenon whereby the introduction of double stranded (ds) RNA into the cytoplasm of the cell results in the specific and efficient degradation of complementary messenger (m) RNA and, therefore, reduced protein production. It was discovered by chance during attempts to develop flowers with increased colour intensity. The specific nature of the inhibition of protein production of cells has resulted in an explosion of research to understand and exploit RNAi. The technique is now established in in vitro systems, and much work is focussed in adapting RNAi for in vivo application. The potential of the technology in understanding physiological and pathological processes is significant, while its development as a therapeutic agent holds much promise as targeted agents. This review will describe the basic biological processes that drive RNAi, indicate current areas of areas research, and forecast future areas of development.
Martineau
Henny M
HM
Scottish Agricultural College, Allan Watt Building, Bush Estate, Penicuik, EH26 0QE, United Kingdom.
Pyrah
Ian T
IT
D000818:Animals; D004345:Drug Industry; D006801:Humans; D034622:RNA Interference; D013672:Technology / Q000379:methods*